Constellation Energy Corporation vs GeneDx Holdings Corp — how do they compare? Constellation Energy Corporation trades at $258 (market cap $91.57B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Constellation Energy Corporation is far larger — about 49.5× GeneDx Holdings Corp's market cap, and Constellation Energy Corporation pays a 0.67% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CEG | WGS | |
|---|---|---|
Market Cap | $91.57B | $1.85B |
Sector | Energy | Technology |
52-Week High | $403.95 | $167.51 |
52-Week Low | $236.50 | $34.51 |
Enterprise Value | $113.24B | $1.85B |
Dividend Yield | 0.67% | — |
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Trailing returns across standard periods
Latest headlines on both assets
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →